A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

Cancer

Volumn 106, Issue 6, 2006, Pages 1339-1346

  Kim, Seung Tai ^a   Park, Joon Oh ^a   Lee, Jeeyun ^a   Lee, Kyu Taek ^a   Lee, Jong Kyun ^a   Choi, Seong Ho ^a   Heo, Jin Seok ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Biliary tract cancer; CA 19 9; Gemcitabine

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; BILIARY TRACT CANCER; BLOOD TOXICITY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33644842475     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21741     Document Type: Article

References (33)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Shin HR, Jung KW, Won YJ, Park JG and 139 KCCR-affiliated Hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat. 2004;36:103-114.
3. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.
4. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg. 1995;19:83-88.
5. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg. 1999;6:122-127.
6. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600.
7. Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425-428.
8. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-656.
9. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965-969.
10. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984;2:1245-1248.
11. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994;51:396-400.
12. Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192-1196.
13. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004;15:770-774.
14. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332-2338.
15. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14:1115-1120.
16. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001;19:4089-4091.
17. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48:783-789.
18. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002;29(6 suppl 20):40-45.
19. Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer. 2004;90:1516-1520.
20. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279-281.
21. Reyes-Vidal J, Gallardo J, Cerda B, et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: Results of the phase II GOCCHI study 2000-13 [abstract]. Proc Am Soc Clin Oncol 2003;22:273. Abstract 1095.
22. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
23. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
24. Okada S, Ishii H, Nose H, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology. 1994;51:515-517.
25. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521-530.
26. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22(4 suppl 11):72-79.
27. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther. 2000;87:227-253.
28. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA 19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol. 2004;10:427-432.
29. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182-1191.
30. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-199.
31. Park JO, Rang WK, Kim TY, et al. A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC) [abstract]. J Clin Oncol. 2005;23(16 suppl):4133.
32. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20:1512-1518.
33. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.